Inactive Instrument

Pharmacyclics, Inc. Share Price

Stocks

End-of-day quote Nasdaq
- ^USD	-

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
21/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
21/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
08/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
05/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
05/03/15	Wall Street closes up slightly ahead of jobs report	RE
05/03/15	AbbVie : CEO says new form of Humira could thwart generics	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
07/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
07/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

05/03/15	Wall Street se reprend un peu dans un climat d'attente
05/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/03/15	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	31/01/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-0.37%	-3.88%	+19.75%	+78.35%	57.39B
LONZA GROUP AG	+1.63%	+0.98%	+3.83%	+38.21%	47.64B
REVOLUTION MEDICINES, INC.	+0.50%	+1.32%	+344.62%	+753.25%	44.29B
IQVIA HOLDINGS INC.	+3.05%	-1.58%	+28.78%	+35.46%	42.5B
BEONE MEDICINES AG	+1.00%	+0.22%	+5.17%	+113.80%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+4.53%	+31.34%	+26.92%	28.53B
BIONTECH SE	+0.76%	-0.89%	-7.44%	-11.43%	24.34B
Average	+1.28%	-0.59%	+53.86%	+131.42%	43.39B
Weighted average by Cap.	+1.52%	-0.84%	+58.06%	+140.75%

Employees

Sector